232 related articles for article (PubMed ID: 26478625)
21. Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England: cost effectiveness modelling study.
Allen K; Pearson-Stuttard J; Hooton W; Diggle P; Capewell S; O'Flaherty M
BMJ; 2015 Sep; 351():h4583. PubMed ID: 26374614
[TBL] [Abstract][Full Text] [Related]
22. Regulation of trans fats: the gap, the Polder, and McDonald's French fries.
Katan MB
Atheroscler Suppl; 2006 May; 7(2):63-6. PubMed ID: 16713390
[TBL] [Abstract][Full Text] [Related]
23. Trans fatty acids and cardiovascular health: translation of the evidence base.
Booker CS; Mann JI
Nutr Metab Cardiovasc Dis; 2008 Jul; 18(6):448-56. PubMed ID: 18468872
[TBL] [Abstract][Full Text] [Related]
24. Fatty acid composition including trans-fatty acids in edible oils and fats: probable intake in Indian population.
Dixit S; Das M
J Food Sci; 2012 Oct; 77(10):T188-99. PubMed ID: 22950538
[TBL] [Abstract][Full Text] [Related]
25. Public health economic evaluation of different European Union-level policy options aimed at reducing population dietary trans fat intake.
Martin-Saborido C; Mouratidou T; Livaniou A; Caldeira S; Wollgast J
Am J Clin Nutr; 2016 Nov; 104(5):1218-1226. PubMed ID: 27680991
[TBL] [Abstract][Full Text] [Related]
26. The evidence of politics in trans-fatty acid regulation in Mexico.
Idris IO; Mensah EA; Gavkalova N
Salud Publica Mex; 2021 Feb; 63(2, Mar-Abr):268-273. PubMed ID: 33989494
[TBL] [Abstract][Full Text] [Related]
27. Projecting cardiovascular deaths averted due to trans fat policies in the Eurasian Economic Union.
Rieger M; Rippin HL; Pinedo A; Whiting S; Farrand C; Wickramasinghe K; Breda JJ
Public Health Nutr; 2023 Dec; 26(S1):s41-s50. PubMed ID: 36184895
[TBL] [Abstract][Full Text] [Related]
28. A prospective study of intake of trans-fatty acids from ruminant fat, partially hydrogenated vegetable oils, and marine oils and mortality from CVD.
Laake I; Pedersen JI; Selmer R; Kirkhus B; Lindman AS; Tverdal A; Veierød MB
Br J Nutr; 2012 Aug; 108(4):743-54. PubMed ID: 22059639
[TBL] [Abstract][Full Text] [Related]
29. Trans unsaturated fatty acids in plasma phospholipids and coronary heart disease: a case-control study.
van de Vijver LP; van Poppel G; van Houwelingen A; Kruyssen DA; Hornstra G
Atherosclerosis; 1996 Sep; 126(1):155-61. PubMed ID: 8879443
[TBL] [Abstract][Full Text] [Related]
30. Labeling of trans fatty acid content in food, regulations and limits-the FDA view.
Moss J
Atheroscler Suppl; 2006 May; 7(2):57-9. PubMed ID: 16713387
[TBL] [Abstract][Full Text] [Related]
31. Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model.
Vreman RA; Goodell AJ; Rodriguez LA; Porco TC; Lustig RH; Kahn JG
BMJ Open; 2017 Aug; 7(8):e013543. PubMed ID: 28775179
[TBL] [Abstract][Full Text] [Related]
32. A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries.
Mason H; Shoaibi A; Ghandour R; O'Flaherty M; Capewell S; Khatib R; Jabr S; Unal B; Sözmen K; Arfa C; Aissi W; Ben Romdhane H; Fouad F; Al-Ali R; Husseini A;
PLoS One; 2014; 9(1):e84445. PubMed ID: 24409297
[TBL] [Abstract][Full Text] [Related]
33. The scientific basis for TFA regulations-is it sufficient? Comments from the USA.
Willett WC
Atheroscler Suppl; 2006 May; 7(2):69-71. PubMed ID: 16716766
[TBL] [Abstract][Full Text] [Related]
34. Trans fatty acids: effects on cardiometabolic health and implications for policy.
Micha R; Mozaffarian D
Prostaglandins Leukot Essent Fatty Acids; 2008; 79(3-5):147-52. PubMed ID: 18996687
[TBL] [Abstract][Full Text] [Related]
35. [Trans fatty acids in the Norwegian diet].
Johansson L; Borgejordet A; Pedersen JI
Tidsskr Nor Laegeforen; 2006 Mar; 126(6):760-3. PubMed ID: 16541169
[TBL] [Abstract][Full Text] [Related]
36. Saturated and trans fatty acids and coronary heart disease.
Woodside JV; McKinley MC; Young IS
Curr Atheroscler Rep; 2008 Dec; 10(6):460-6. PubMed ID: 18937892
[TBL] [Abstract][Full Text] [Related]
37. Dietary intake of trans fatty acids and systemic inflammation in women.
Mozaffarian D; Pischon T; Hankinson SE; Rifai N; Joshipura K; Willett WC; Rimm EB
Am J Clin Nutr; 2004 Apr; 79(4):606-12. PubMed ID: 15051604
[TBL] [Abstract][Full Text] [Related]
38. Trans fatty acids (TFA): analysis, occurrence, intake and clinical relevance.
Steinhart H; Rickert R; Winkler K
Eur J Med Res; 2003 Aug; 8(8):358-62. PubMed ID: 12915330
[TBL] [Abstract][Full Text] [Related]
39. Platelet trans fatty acids in relation to angiographically assessed coronary artery disease.
Hodgson JM; Wahlqvist ML; Boxall JA; Balazs ND
Atherosclerosis; 1996 Feb; 120(1-2):147-54. PubMed ID: 8645355
[TBL] [Abstract][Full Text] [Related]
40. The future impact of population growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease Policy Model-China.
Moran A; Zhao D; Gu D; Coxson P; Chen CS; Cheng J; Liu J; He J; Goldman L
BMC Public Health; 2008 Nov; 8():394. PubMed ID: 19036167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
